CN118047669A - 一种铁催化醌类化合物甲基化的方法 - Google Patents
一种铁催化醌类化合物甲基化的方法 Download PDFInfo
- Publication number
- CN118047669A CN118047669A CN202410203401.0A CN202410203401A CN118047669A CN 118047669 A CN118047669 A CN 118047669A CN 202410203401 A CN202410203401 A CN 202410203401A CN 118047669 A CN118047669 A CN 118047669A
- Authority
- CN
- China
- Prior art keywords
- mmol
- methylation
- iron
- ferrous
- ferric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 238000007069 methylation reaction Methods 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 37
- 230000011987 methylation Effects 0.000 title claims abstract description 30
- 229910052742 iron Inorganic materials 0.000 title claims abstract description 23
- 150000004053 quinones Chemical class 0.000 title claims abstract description 15
- 238000006555 catalytic reaction Methods 0.000 title description 7
- 238000006243 chemical reaction Methods 0.000 claims abstract description 79
- 239000002904 solvent Substances 0.000 claims abstract description 30
- -1 quinone compound Chemical class 0.000 claims abstract description 28
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims abstract description 27
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003054 catalyst Substances 0.000 claims abstract description 17
- 239000003446 ligand Substances 0.000 claims abstract description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 14
- 239000007800 oxidant agent Substances 0.000 claims abstract description 13
- 150000001413 amino acids Chemical class 0.000 claims abstract description 12
- 230000001590 oxidative effect Effects 0.000 claims abstract description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 7
- 150000002978 peroxides Chemical class 0.000 claims abstract description 6
- 150000001412 amines Chemical class 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 120
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 54
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 229940024606 amino acid Drugs 0.000 claims description 14
- BDCFWIDZNLCTMF-UHFFFAOYSA-N 2-phenylpropan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1 BDCFWIDZNLCTMF-UHFFFAOYSA-N 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 11
- UCRQQAQWMSPPFY-UHFFFAOYSA-N 2-(3,5-dimethylphenyl)propan-2-ol Chemical compound CC1=CC(C)=CC(C(C)(C)O)=C1 UCRQQAQWMSPPFY-UHFFFAOYSA-N 0.000 claims description 10
- AIJGZNWGLXPXLF-UHFFFAOYSA-N 2-(3-methoxyphenyl)propan-2-ol Chemical compound COC1=CC=CC(C(C)(C)O)=C1 AIJGZNWGLXPXLF-UHFFFAOYSA-N 0.000 claims description 10
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 claims description 10
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- AOGYBHJTXLXRSM-UHFFFAOYSA-N 2-(4-bromophenyl)propan-2-ol Chemical compound CC(C)(O)C1=CC=C(Br)C=C1 AOGYBHJTXLXRSM-UHFFFAOYSA-N 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 8
- UALUYGFVNLQVFT-UHFFFAOYSA-N 2-(2-chlorophenyl)propan-2-ol Chemical compound CC(C)(O)C1=CC=CC=C1Cl UALUYGFVNLQVFT-UHFFFAOYSA-N 0.000 claims description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 8
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 claims description 8
- SLFZJKUFAVHARP-UHFFFAOYSA-N 4-(2-hydroxypropan-2-yl)benzoic acid Chemical compound CC(C)(O)C1=CC=C(C(O)=O)C=C1 SLFZJKUFAVHARP-UHFFFAOYSA-N 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- BMYNFMYTOJXKLE-UHFFFAOYSA-N DL-isoserine Natural products NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 6
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 6
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 claims description 6
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 claims description 6
- AQTUACKQXJNHFQ-LURJTMIESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(O)=O AQTUACKQXJNHFQ-LURJTMIESA-N 0.000 claims description 5
- XMNIXWIUMCBBBL-UHFFFAOYSA-N 2-(2-phenylpropan-2-ylperoxy)propan-2-ylbenzene Chemical compound C=1C=CC=CC=1C(C)(C)OOC(C)(C)C1=CC=CC=C1 XMNIXWIUMCBBBL-UHFFFAOYSA-N 0.000 claims description 5
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 claims description 5
- 229960003067 cystine Drugs 0.000 claims description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 5
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 5
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 claims description 4
- MIINHRNQLVVCEW-UHFFFAOYSA-N 132-16-1 Chemical compound [Fe+2].C12=CC=CC=C2C(N=C2[N-]C(C3=CC=CC=C32)=N2)=NC1=NC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 MIINHRNQLVVCEW-UHFFFAOYSA-N 0.000 claims description 4
- LCPVQAHEFVXVKT-UHFFFAOYSA-N 2-(2,4-difluorophenoxy)pyridin-3-amine Chemical compound NC1=CC=CN=C1OC1=CC=C(F)C=C1F LCPVQAHEFVXVKT-UHFFFAOYSA-N 0.000 claims description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 4
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 4
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 4
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 claims description 4
- 239000004158 L-cystine Substances 0.000 claims description 4
- 239000012425 OXONE® Substances 0.000 claims description 4
- MCDLETWIOVSGJT-UHFFFAOYSA-N acetic acid;iron Chemical compound [Fe].CC(O)=O.CC(O)=O MCDLETWIOVSGJT-UHFFFAOYSA-N 0.000 claims description 4
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium peroxydisulfate Substances [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 claims description 4
- VAZSKTXWXKYQJF-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)OOS([O-])=O VAZSKTXWXKYQJF-UHFFFAOYSA-N 0.000 claims description 4
- 229910001870 ammonium persulfate Inorganic materials 0.000 claims description 4
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 4
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960002089 ferrous chloride Drugs 0.000 claims description 4
- 229940062993 ferrous oxalate Drugs 0.000 claims description 4
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 4
- OWZIYWAUNZMLRT-UHFFFAOYSA-L iron(2+);oxalate Chemical compound [Fe+2].[O-]C(=O)C([O-])=O OWZIYWAUNZMLRT-UHFFFAOYSA-L 0.000 claims description 4
- SHXXPRJOPFJRHA-UHFFFAOYSA-K iron(iii) fluoride Chemical compound F[Fe](F)F SHXXPRJOPFJRHA-UHFFFAOYSA-K 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- HJKYXKSLRZKNSI-UHFFFAOYSA-I pentapotassium;hydrogen sulfate;oxido sulfate;sulfuric acid Chemical compound [K+].[K+].[K+].[K+].[K+].OS([O-])(=O)=O.[O-]S([O-])(=O)=O.OS(=O)(=O)O[O-].OS(=O)(=O)O[O-] HJKYXKSLRZKNSI-UHFFFAOYSA-I 0.000 claims description 4
- 229960001153 serine Drugs 0.000 claims description 4
- CHQMHPLRPQMAMX-UHFFFAOYSA-L sodium persulfate Substances [Na+].[Na+].[O-]S(=O)(=O)OOS([O-])(=O)=O CHQMHPLRPQMAMX-UHFFFAOYSA-L 0.000 claims description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 3
- ZYJPUMXJBDHSIF-LLVKDONJSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-LLVKDONJSA-N 0.000 claims description 3
- OYXZPXVCRAAKCM-SANMLTNESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C1=NC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OYXZPXVCRAAKCM-SANMLTNESA-N 0.000 claims description 3
- LFKXWKGYHQXRQA-FDGPNNRMSA-N (z)-4-hydroxypent-3-en-2-one;iron Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LFKXWKGYHQXRQA-FDGPNNRMSA-N 0.000 claims description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 3
- 229940035437 1,3-propanediol Drugs 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- WVYWICLMDOOCFB-UHFFFAOYSA-N 4-methyl-2-pentanol Chemical compound CC(C)CC(C)O WVYWICLMDOOCFB-UHFFFAOYSA-N 0.000 claims description 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 3
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims description 3
- 229930182831 D-valine Natural products 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- FFFHZYDWPBMWHY-UHFFFAOYSA-N L-Homocysteine Natural products OC(=O)C(N)CCS FFFHZYDWPBMWHY-UHFFFAOYSA-N 0.000 claims description 3
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 3
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- XCIXKGXIYUWCLL-UHFFFAOYSA-N cyclopentanol Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 claims description 3
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 claims description 3
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 claims description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 3
- IMBKASBLAKCLEM-UHFFFAOYSA-L ferrous ammonium sulfate (anhydrous) Chemical compound [NH4+].[NH4+].[Fe+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O IMBKASBLAKCLEM-UHFFFAOYSA-L 0.000 claims description 3
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 3
- 239000011790 ferrous sulphate Substances 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 3
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 3
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 claims description 3
- OSHOQERNFGVVRH-UHFFFAOYSA-K iron(3+);trifluoromethanesulfonate Chemical compound [Fe+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F OSHOQERNFGVVRH-UHFFFAOYSA-K 0.000 claims description 3
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 3
- 229910000360 iron(III) sulfate Inorganic materials 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 229960002898 threonine Drugs 0.000 claims description 3
- FEONEKOZSGPOFN-UHFFFAOYSA-K tribromoiron Chemical compound Br[Fe](Br)Br FEONEKOZSGPOFN-UHFFFAOYSA-K 0.000 claims description 3
- XPEMYYBBHOILIJ-UHFFFAOYSA-N trimethyl(trimethylsilylperoxy)silane Chemical compound C[Si](C)(C)OO[Si](C)(C)C XPEMYYBBHOILIJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004441 tyrosine Drugs 0.000 claims description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 2
- WFUGQJXVXHBTEM-UHFFFAOYSA-N 2-hydroperoxy-2-(2-hydroperoxybutan-2-ylperoxy)butane Chemical compound CCC(C)(OO)OOC(C)(CC)OO WFUGQJXVXHBTEM-UHFFFAOYSA-N 0.000 claims description 2
- JSGVZVOGOQILFM-UHFFFAOYSA-N 3-methoxy-1-butanol Chemical compound COC(C)CCO JSGVZVOGOQILFM-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims description 2
- 229930195711 D-Serine Natural products 0.000 claims description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 2
- 229930028154 D-arginine Natural products 0.000 claims description 2
- 229930182820 D-proline Natural products 0.000 claims description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 2
- 229910021575 Iron(II) bromide Inorganic materials 0.000 claims description 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
- 229930182821 L-proline Natural products 0.000 claims description 2
- MDXGYYOJGPFFJL-QMMMGPOBSA-N N(alpha)-t-butoxycarbonyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)OC(C)(C)C MDXGYYOJGPFFJL-QMMMGPOBSA-N 0.000 claims description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 235000003704 aspartic acid Nutrition 0.000 claims description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
- 229940046149 ferrous bromide Drugs 0.000 claims description 2
- 229940076136 ferrous iodide Drugs 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- PANJMBIFGCKWBY-UHFFFAOYSA-N iron tricyanide Chemical compound N#C[Fe](C#N)C#N PANJMBIFGCKWBY-UHFFFAOYSA-N 0.000 claims description 2
- LHOWRPZTCLUDOI-UHFFFAOYSA-K iron(3+);triperchlorate Chemical compound [Fe+3].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O LHOWRPZTCLUDOI-UHFFFAOYSA-K 0.000 claims description 2
- GYCHYNMREWYSKH-UHFFFAOYSA-L iron(ii) bromide Chemical compound [Fe+2].[Br-].[Br-] GYCHYNMREWYSKH-UHFFFAOYSA-L 0.000 claims description 2
- BQZGVMWPHXIKEQ-UHFFFAOYSA-L iron(ii) iodide Chemical compound [Fe+2].[I-].[I-] BQZGVMWPHXIKEQ-UHFFFAOYSA-L 0.000 claims description 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229960002429 proline Drugs 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 claims description 2
- JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 claims 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 claims 2
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 claims 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims 1
- 235000019393 L-cystine Nutrition 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 38
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000007613 environmental effect Effects 0.000 abstract description 4
- 125000000524 functional group Chemical group 0.000 abstract description 3
- 150000001491 aromatic compounds Chemical class 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000002920 hazardous waste Substances 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 64
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 52
- 239000003208 petroleum Substances 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 26
- 238000003786 synthesis reaction Methods 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 23
- 238000004440 column chromatography Methods 0.000 description 20
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 230000000694 effects Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000003197 catalytic effect Effects 0.000 description 6
- 238000013375 chromatographic separation Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012022 methylating agents Substances 0.000 description 3
- 229910000510 noble metal Inorganic materials 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- PGJLOGNVZGRMGX-UHFFFAOYSA-L iron(2+);trifluoromethanesulfonate Chemical compound [Fe+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F PGJLOGNVZGRMGX-UHFFFAOYSA-L 0.000 description 2
- PFPIMAZLJXJVAN-UHFFFAOYSA-K iron(3+);triperchlorate;hydrate Chemical compound O.[Fe+3].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O PFPIMAZLJXJVAN-UHFFFAOYSA-K 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- CWPKTBMRVATCBL-UHFFFAOYSA-N 3-[1-[1-[(2-methylphenyl)methyl]piperidin-4-yl]piperidin-4-yl]-1h-benzimidazol-2-one Chemical compound CC1=CC=CC=C1CN1CCC(N2CCC(CC2)N2C(NC3=CC=CC=C32)=O)CC1 CWPKTBMRVATCBL-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 101000730670 Homo sapiens Phospholipase D2 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 101000761444 Loxosceles laeta Dermonecrotic toxin Proteins 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 102100032983 Phospholipase D2 Human genes 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- JQRLYSGCPHSLJI-UHFFFAOYSA-N [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JQRLYSGCPHSLJI-UHFFFAOYSA-N 0.000 description 1
- 150000008061 acetanilides Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- VEPSWGHMGZQCIN-UHFFFAOYSA-H ferric oxalate Chemical compound [Fe+3].[Fe+3].[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O.[O-]C(=O)C([O-])=O VEPSWGHMGZQCIN-UHFFFAOYSA-H 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- LZKLAOYSENRNKR-LNTINUHCSA-N iron;(z)-4-oxoniumylidenepent-2-en-2-olate Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LZKLAOYSENRNKR-LNTINUHCSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MBXNQZHITVCSLJ-UHFFFAOYSA-N methyl fluorosulfonate Chemical group COS(F)(=O)=O MBXNQZHITVCSLJ-UHFFFAOYSA-N 0.000 description 1
- ZSBDPRIWBYHIAF-UHFFFAOYSA-N n-acetylacetamide Chemical compound CC(=O)NC(C)=O ZSBDPRIWBYHIAF-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2204—Organic complexes the ligands containing oxygen or sulfur as complexing atoms
- B01J31/2208—Oxygen, e.g. acetylacetonates
- B01J31/2226—Anionic ligands, i.e. the overall ligand carries at least one formal negative charge
- B01J31/2243—At least one oxygen and one nitrogen atom present as complexing atoms in an at least bidentate or bridging ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B37/00—Reactions without formation or introduction of functional groups containing hetero atoms, involving either the formation of a carbon-to-carbon bond between two carbon atoms not directly linked already or the disconnection of two directly linked carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
- C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
- C07C51/353—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/80—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings
- C07C59/82—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings the keto group being part of a ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
- C07F7/083—Syntheses without formation of a Si-C bond
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/84—Metals of the iron group
- B01J2531/842—Iron
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/20—Acenaphthenes; Hydrogenated acenaphthenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种铁催化醌类化合物甲基化的方法,该方法包括如下步骤:在溶剂中,以2‑芳基‑2‑丙醇类物质为甲基化试剂、过氧化物为氧化剂,铁为催化剂、氨基酸或其衍生物为配体,氧化芳香族化合物的C(sp2)‑H键发生甲基化反应生成甲基取代的醌类化合物。本发明方法具有催化剂来源广泛、廉价和环保的优势;氧化剂来源广泛、廉价和不产生危险性废物;甲基化试剂温和、稳定和廉价;反应条件温和、选择性高和产率高;底物来源广泛且稳定;底物官能团相容性好且底物的适用范围广;复杂分子和天然产物可兼容,能很好的实现醌类化合物的甲基化。在优化的反应条件之下,目标产品分离后产率可以达到80%。
Description
技术领域
本发明属于催化合成技术和精细化学品合成领域,具体涉及一种铁催化醌类化合物甲基化的方法,尤其是铁催化合适的氧化剂氧化醌类化合物实现醌的C(sp2)-H键直接甲基化的方法。
背景技术
甲基是自然界中最小的有机基团,广泛存在于药物分子和天然产物中。甲基化反应是药物化学的基本反应,在药物分子中引入甲基会很大程度上改变其生物活性,例如引入一个甲基至药物分子PLD2 IC50中,可以将其药效提升590倍;科研工作者们称这种现象为“神奇的甲基效应”(HeikeTim Cernak*Angew.Chem.Int.Ed.,2013,52(47):12256-12267.)。因此甲基化反应一直是化学领域研究的热点,高效的甲基化方法也一直被研究人员所探索。到目前为止,甲基化反应已经取得了很大的进展。
自Minisci(Minisci F.,Bernardi R.Tetrahedron,1971,27(15):3575-3579.)等人的早期工作以来,自由基型的甲基化反应取得了成功的进展;同时,由过渡金属催化C-H键活化的甲基化反应也在过去的几十年也取得了飞速的发展。通过交叉偶联获得甲基化产物的方法,具有良好的化学选择性,但是需要对底物进行预官能团化,增加了反应步骤与成本。相比之下,通过C-H键活化进行甲基化反应的方法更受人们的欢迎,近几十年来各研究者在该方面也取得了很大的进步,但是仍然有一些地方需要继续改进。例如,Tremont课题组(Samuel J.Tremont,Hayat Ur RahmanJ.Am.Chem.Soc.1984,106,19,5759–5760)在1984年报道了一项乙酰苯胺类化合物邻位C-H键甲基化的反应,该反应以计量的钯为催化剂,以高计量的碘甲烷为甲基化试剂,虽然实现了C-H键的甲基化,但是不够经济环保;2019年,申亮课题组(Zhengbao Xu*,,Liang Shen*,Synlett 2019;30(16):1909-1913)使用叔丁醇作为甲基化试剂,在铁催化下,实现了醌类化合物的甲基化过程;但其使用了昂贵的高碘试剂,且反应的进程不易控制,易形成多甲基化产物;同年,王继宇团队(Jian Yang,Ji-YuWang*,Tetrahedron,2019,75(50):130729.),使用TBPB作为氧化剂和甲基源,但使用了贵金属铋催化,不具经济性。以上方法对于合成甲基化的醌类化合物取得了阶段性的进展,但仍存在需要贵金属催化的不足之处,存在多甲基化的选择性问题,以及难以用于复杂分子的后期修饰,导致其进行大规模应用受到限制;因此,开发一种活性高,选择性好的廉价金属催化实现复杂醌类分子的甲基化的方法显得尤为重要。
发明内容
发明目的:针对现有技术存在的问题,本发明提供一种铁催化醌类化合物甲基化的方法,包括如下步骤:以单取代或双取代的2-芳基-2-丙醇为甲基化试剂、过氧化物为氧化剂,铁为催化剂、氨基酸或其衍生物为配体,在溶剂中氧化醌类化合物的C(sp2)-H键发生甲基化反应生成甲基取代的醌类化合物;
反应通式表示如下:
式中:所述R1表示醌类化合物中芳环上的取代基,R1单取代或双取代苯环上的氢;R2表示醌类化合物双键上的取代基,R2单取代双键上的氢;R3表示2-芳基-2-丙醇中芳基上的取代基,R3单取代或多取代芳环上的氢。
其中,所述R1表示醌类化合物中芳环上的取代基,R1单取代或双取代苯环上的氢,R1为硝基、甲氧基或甲基等。
其中,所述R2为氢、甲基、甲氧基、乙氧基、异丙氧基苯氧基、卤素、乙酰氧基或甲硫基等。
其中,以R3表示2-芳基-2-丙醇中芳基上的取代基,R3单取代或多取代芳环上的氢,R3为氢、3-甲氧基、2-氯、4-溴、3,5-二甲基或4-羧基等。
其中,所述单取代或双取代的2-芳基-2-丙醇选自2-苯基-2-丙醇(CAS:617-94-7)、2-(3-甲氧基苯基)丙-2-醇(CAS:55311-42-7)、2-(2-氯苯基)丙-2-醇(CAS:3670-15-3)、2-(4-溴苯基)丙-2-醇(CAS:2077-19-2)、2-(3,5-二甲基苯基)丙-2-醇(CAS:34696-74-7)或4-(2-羟基-2-丙基)苯甲酸(CAS:3609-50-5)等。
其中,所述铁选自三氟甲磺酸亚铁、三氟甲磺酸铁、氯化亚铁、乙酰丙酮亚铁、乙酰丙酮铁、铁氰化铁、醋酸亚铁、苯甲酰丙酮铁、硫酸亚铁、硫酸亚铁铵、硫酸铁、草酸亚铁、草酸铁、氟化亚铁、氟化铁、溴化亚铁、溴化铁、碘化亚铁、氯化亚铁、三氯化铁、高氯酸铁水合物、1,1'-双(二苯基膦)二茂铁、酞菁亚铁、硝酸铁、氧化铁或四氧化三铁中的任意一种或者多种。
其中,所述配体选自S-乙酰氨基甲基-N-叔丁氧羰基-L-半胱氨酸、N-乙酰-L-半胱氨酸、N,N'-双(叔丁氧羰基)-L-胱氨酸、L-丝氨酸、D-胱氨酸、天冬氨酸、D-精氨酸、异丝氨酸、L-苏氨酸、L-酪氨酸、BOC-L-脯氨酸、BOC-甘氨酸-甘氨酸-甘氨酸、2-烯丙基-N-FMOC-L-甘氨酸、BOC-D-苯丙氨酸、L-半胱氨酸、D-丝氨酸、β-硫基缬氨酸、D-脯氨酸、D-缬氨酸、L-脯氨酸、L-苯丙氨酸、N-BOC-N'-三苯甲基-L-组氨酸、L-色氨酸、N-BOC-L-亮氨酸、L-组氨酸、BOC-L-谷氨酸、L-胱氨酸或者L-高胱氨酸中的任意一种或者多种。
其中,所述氧化剂选自过硫酸钾、过硫酸铵、过硫酸钠、叔丁基过氧化氢、过氧化氢、过氧乙酸、间氯过氧苯甲酸、过氧化苯甲酰、二叔丁基过氧化物、单过硫酸氢钾、过氧化二异丙苯、2-过氧化丁酮或者双(三甲基硅基)过氧化物中的任意一种或者多种。
其中,所述溶剂为有机溶剂、水或有机溶剂的水溶液,所述有机溶剂选自甲醇、乙醇、乙二醇、正丙醇、异丙醇、1,3-丙二醇、甘油、正丁醇、异丁醇、叔丁醇、三氟乙醇、2-甲基-2-丁醇、3-甲氧基丁醇、仲丁醇、叔戊醇、4-甲基-2-戊醇、异戊醇、2-戊醇、3-戊醇、环戊醇、正戊醇、聚乙二醇200-10000、乙腈、苯腈、甲苯、丙酮、二氯甲烷、1,2-二氯乙烷、二甲亚砜、N,N-二甲酰胺、N,N-二乙酰胺、乙酸乙酯、1,4-二氧六环或四氢呋喃,所述溶剂为有机溶剂的水溶液时,所述有机溶剂与水的体积比为1:(0.1~10)。
其中,所述醌类化合物、单取代或双取代的2-芳基-2-丙醇、过氧化物、氨基酸或其衍生物、铁催化剂的摩尔比为1:(1.2~50):(2~50):(0.002~20):(0.001~10);反应的温度为40~120℃、时间为0.5~48小时。
本发明的方法中铁的催化剂具有天然丰度大、价格低廉和毒性很小的特点,使用了特定的氨基酸类配体,与铁催化剂进行配位,形成了高活性催化物种,这种催化物种和氧化剂、溶剂等共同作用,具有高的活性和选择性。此外,本发明的方法中使用温和的试剂,温和的环境,解决了反应条件苛刻的问题;单取代或双取代的2-苯基-2-丙醇其成本低、易于获得,无毒性和爆炸性;无需预官能团化,铁为催化剂,不用贵金属,并且效果显著。本发明方法中首次采用特定的单取代或双取代的2-苯基-2-丙醇作甲基化反应的甲基源,相较于现有已报道的未使用此类甲基源的方案,本方法具有高的转化率与经济性、环保性。
本发明首次将铁-氨基酸配位物种应用于醌类甲基化反应中,相对于之前的贵金属催化展现出了高催化活性与稳定性。对于原料而言,对底物中官能团的兼容性更广,并首次使用具有高的转化率与经济性、环保性的2-苯基-2-丙醇作为甲基源。本发明巧妙的使用氨基酸类化合物为配体来调控廉价易得铁催化甲基化醌具有高的活性和理想的选择性,并能用于复杂分子的后期修饰,解决了该类反应存在的系列挑战性问题,使该类转化有更加广泛的用途,特别是在药物活性分子合成方面。
有益效果:与现有技术相比,本发明具有如下优点:
(1)本发明提供了一种氨基酸或其衍生物类配体促进的铁催化氧化醌类化合物甲基化的方法,该方法只需一步反应,无需酸或碱的参与,且具有催化剂、配体和氧化剂廉价、来源广泛和环保的独特优势;反应条件温和,且选择性高和产率高;底物来源广泛、稳定和易于处理;底物官能团相容性好且底物的适用范围广;反应具有适用于复杂小分子甲基化的优势;
(2)本发明提供的甲基化方法简单易行和安全,一步法直接得到醌类合物的甲基化产物,在优化的反应条件之下,目标产品分离后产率可以高达80%,是一种通用、高效、经济和环境友好的甲基化的方法;
(3)本发明的方法之所以能够使用理想的铁为催化剂进行反应,关键在于使用了氨基酸类配体,与铁催化剂进行配位,形成了高活性催化物种,使反应能够在非常温和的条件下进行芳香族化合物的甲基化反应,特别是对复杂的底物也能取得理想的催化效果。本发明巧妙的使用氨基酸类化合物为配体来调控廉价易得铁催化甲基化醌具有高的活性和理想的选择性,并能用于复杂分子的后期修饰,解决了该类反应存在的系列挑战性问题,使该类转化有更加广泛的用途,特别是在药物活性分子合成方面。
(4)本发明的方法合成的甲基化的醌类化合物可以作为药物或生物活性分子,同时是重要的有机中间体,广泛应用于医药中间体、杂环和高附加值精细化学品的合成。
具体实施方式
根据下述实施例,可以更好地理解本发明。然而,本领域的技术人员容易理解,实施例所描述的内容仅用于说明本发明,而不应当也不会限制权利要求书中所详细描述的本发明。
实施例中所述实验方法,如无特殊说明,均为常规方法;所述试剂和材料,如无特殊说明,均可从商业途径或通过现有技术简单制备获得。
实施例中的底物和产物的具体结构见表1。
本发明实施例中底物均为已知化合物。本发明中的产物中化合物8、9、24、25为首次合成的化合物,已提供核磁质谱数据,其余为已知化合物。
其中,2-苯基-2-丙醇(CAS:617-94-7)、2-(3-甲氧基苯基)丙-2-醇(CAS:55311-42-7)、2-(2-氯苯基)丙-2-醇(CAS:3670-15-3)、2-(4-溴苯基)丙-2-醇(CAS:2077-19-2)、2-(3,5-二甲基苯基)丙-2-醇(CAS:34696-74-7)、4-(2-羟基-2-丙基)苯甲酸(CAS:3609-50-5)。
实施例1
化合物1的合成
空气中,25mL反应瓶中依次加入硫酸铁(0.06mmol),BOC-L-脯氨酸(0.09mmol),底物1a(0.5mmol),乙醇(1.5mL)和水(0.5mL),2-苯基-2-丙醇(1mmol)和过硫酸钾(2mmol)。室温下混合均匀后,反应混合物在80℃下回流反应5h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=40:1)得到产物1,其产率75%。
实施例2
化合物2的合成
空气中,25mL反应瓶中依次加入酞菁亚铁(0.01mmol),L-色氨酸(0.2mmol),底物2a(0.5mmol),二甲基亚砜(1.5mL)和水(0.5mL),2-(3-甲氧基苯基)丙-2-醇(1.5mmol)和过氧化二异丙苯(1mmol)。室温下混合均匀后,反应混合物在65℃下回流反应4h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=30:1)得到产物2,其产率68%。
实施例3
化合物3的合成
空气中,25mL反应瓶中依次加入氟化铁(0.035mmol),BOC-L-谷氨酸(0.04mmol),底物3a(0.5mmol),二氯甲烷(2.0mL),2-(2-氯苯基)丙-2-醇(1.5mmol)和单过硫酸氢钾(1.2mmol)。室温下混合均匀后,反应混合物在55℃下回流反应6h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=30:1)得到产物3,其产率69%。
实施例4
化合物4的合成
空气中,25mL反应瓶中依次加入铁氰化铁(0.02mmol),S-乙酰氨基甲基-N-叔丁氧羰基-L-半胱氨酸(0.08mmol),底物4a(0.5mmol),乙醇(2.0mL)和水(0.5mL),2-(4-溴苯基)丙-2-醇(2mmol)和间氯过氧苯甲酸(1.5mmol)。室温下混合均匀后,反应混合物在90℃下反应3h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:二氯甲烷V/V=20:1)得到产物4,其产率71%。
1H NMR(400MHz,CDCl3):δ8.06-8.01(m,2H),7.70-7.64(m,2H),5.02-4.93(m,1H),2.09(s,3H),1.35ppm(d,J=6.2Hz,6H);13C NMR(100MHz,CDCl3):δ185.8,181.4,156.8,133.6,133.5,133.1,132.1,131.5,126.13,126.1,76.2,23.0,9.7ppm;Mp:116.3–117.9℃.
实施例5
化合物5的合成
空气中,25mL反应瓶中依次加入草酸亚铁(0.07mmol),BOC-甘氨酸-甘氨酸-甘氨酸(0.1mmol),底物5a(0.5mmol),丙酮(2.0mL)和水(1.0mL),2-(3,5-二甲基苯基)丙-2-醇(2.5mmol)和过氧化苯甲酰(1.2mmol)。室温下混合均匀后,反应混合物在100℃下反应2h。反应结束,加入水5mL,并用乙醚萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=40:1)得到产物5,其产率73%。
实施例6
化合物6的合成
空气中,25mL反应瓶中依次加入草酸铁(0.08mmol),L-组氨酸(0.7mmol),底物6a(0.5mmol),N,N-二乙酰胺(1.5mL)和水(0.5mL),4-(2-羟基-2-丙基)苯甲酸(3mmol)和叔丁基过氧化氢(3mmol)。室温下混合均匀后,反应混合物在75℃下反应4h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=40:1)得到产物6,其产率62%。
实施例7
化合物7的合成
空气中,25mL反应瓶中依次加入硝酸铁(0.03mmol),BOC-L-谷氨酸(0.1mmol),底物7a(0.5mmol),异戊醇(2.0mL)和水(1.5mL),2-苯基-2-丙醇(2.5mmol)和过氧乙酸(1.5mmol)。室温下混合均匀后,反应混合物在95℃下反应1h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=20:1)得到产物7,其产率77%。
1H NMR(400MHz,CDCl3):δ8.06-8.01(m,2H),7.70-7.64(m,2H),5.02-4.93(m,1H),2.09(s,3H),1.35ppm(d,J=6.2Hz,6H);13C NMR(100MHz,CDCl3):δ185.8,181.4,156.8,133.6,133.5,133.1,132.1,131.5,126.13,126.1,76.2,23.0,9.7ppm;Mp:116.3–117.9℃.
实施例8
化合物8的合成
空气中,25mL反应瓶中依次加入1,1'-双(二苯基膦)二茂铁(0.11mmol),N,N'-双(叔丁氧羰基)-L-胱氨酸(0.4mmol),底物8a(0.5mmol),4-甲基-2-戊醇(2.0mL)水(1.5mL),2-(3-甲氧基苯基)丙-2-醇(2mmol)和过硫酸钠(1.5mmol)。室温下混合均匀后,反应混合物在100℃下反应6h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=15:1)得到产物8,其产率80%。
1H NMR(400MHz,CDCl3):δ8.09-8.05(m,2H),7.71-7.68(m,2H),2.89(t,J=7.8Hz,2H),2.63(t,J=7.8Hz,2H),2.45(q,J=7.3Hz,2H),2.21(s,3H),1.07ppm(t,J=7.3Hz,3H);13C NMR(100MHz,CDCl3):δ209.8,185.0,184.7,145.9,144.0,133.5,133.4,132.1,132.07,126.3,126.2,40.5,35.8,21.7,12.7,7.8ppm;HRMS(ESI)calcd.for C16H16O3Na+[M+Na+]m/z 279.0992,found 279.0992.
实施例9
化合物9的合成
空气中,25mL反应瓶中依次加入乙酰丙酮铁(0.08mmol),L-丝氨酸(0.1mmol),底物9a(0.5mmol),1,3-丙二醇(1.0mL)和水(1.0mL),2-(2-氯苯基)丙-2-醇(1.5mmol)和过氧乙酸(2mmol)。室温下混合均匀后,反应混合物在80℃下反应12h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=15:1)得到产物9,其产率74%。
1H NMR(400MHz,CDCl3):δ8.06-8.01(m,2H),7.70-7.64(m,2H),5.02-4.93(m,1H),2.09(s,3H),1.35ppm(d,J=6.2Hz,6H);13C NMR(100MHz,CDCl3):δ185.8,181.4,156.8,133.6,133.5,133.1,132.1,131.5,126.13,126.1,76.2,23.0,9.7ppm;Mp:116.3–117.9℃;HRMS(ESI)calcd.for C23H22O3H+[M+H+]m/z347.16417,found 347.1644.
实施例10
化合物10的合成
空气中,25mL反应瓶中依次加入硫酸亚铁(0.06mmol),L-苯丙氨酸(0.1mmol),底物10a(0.5mmol),四氢呋喃(2.0mL)和水(1.0mL),2-(4-溴苯基)丙-2-醇(1.5mmol)和过氧化氢(1.3mmol)。室温下混合均匀后,反应混合物在70℃下反应9h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,用水洗涤(5mL×3),收集有机相,减压蒸除溶剂后柱层析分离(石油醚:乙醚V/V=40:1)得到产物10,其产率62%。
1H NMR(400MHz,CDCl3):δ8.06-8.01(m,2H),7.70-7.64(m,2H),5.02-4.93(m,1H),2.09(s,3H),1.35ppm(d,J=6.2Hz,6H);13C NMR(100MHz,CDCl3):δ185.8,181.4,156.8,133.6,133.5,133.1,132.1,131.5,126.13,126.1,76.2,23.0,9.7ppm;Mp:116.3–117.9℃.
实施例11
化合物11的合成
空气中,25mL反应瓶中依次加入氟化铁(0.03mmol),L-丝氨酸(0.04mmol),底物11a(0.5mmol),1,4-二氧六环(2.0mL)和水(0.2mL),2-(3,5-二甲基苯基)丙-2-醇(1mmol)和过氧化二异丙苯(1mmol)。室温下混合均匀后,反应混合物在50℃下反应18h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,用水洗涤(5mL×3),收集有机相,减压蒸除溶剂后柱层析分离(石油醚:乙醚V/V=10:3)得到产物11,其产率68%。
实施例12
化合物12的合成
空气中,25mL反应瓶中依次加入三氟甲磺酸铁(0.02mmol),β-硫基缬氨酸(0.3mmol)胱氨酸(0.04mmol),底物12a(0.5mmol),乙腈(1.0mL)和水(1.0mL),4-(2-羟基-2-丙基)苯甲酸(2mmol)和过硫酸钾(2mmol)。室温下混合均匀后,反应混合物在100℃下反应2h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=20:1)得到产物12,其产率62%。
实施例13
化合物13的合成
空气中,25mL反应瓶中依次加入高氯酸铁(III)水合物(0.01mmol),BOC-甘氨酸-甘氨酸-甘氨酸(0.02mmol),底物13a(0.5mmol),1,2-二氯乙烷(2.0mL)和水(0.4mL),2-(4-溴苯基)丙-2-醇(2.5mmol)和双(三甲基硅基)过氧化物(1mmol)。室温下混合均匀后,反应混合物在80℃下反应3h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=15:1)得到产物13,其产率64%。
实施例14
化合物14的合成
空气中,25mL反应瓶中依次加入四氧化三铁(0.16mmol),β-硫基缬氨酸(0.3mmol),底物14a(0.5mmol),二甲基亚砜(2.0mL)和水(0.5mL),2-(3,5-二甲基苯基)丙-2-醇(2mmol)和过硫酸铵(1.5mmol)。室温下混合均匀后,反应混合物在60℃下反应2h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=20:1)得到产物14,其产率60%。
实施例15
化合物15的合成
常压氮气中,25mL反应瓶中依次加入乙酰丙酮亚铁(0.09mmol),2-烯丙基-N-FMOC-L-甘氨酸(0.03mmol),底物15a(0.5mmol),二甲基亚砜(1.5mL)和水(0.5mL),2-苯基-2-丙醇(2mmol)和过硫酸铵(2mmol)。室温下混合均匀后,反应混合物在90℃下反应6h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=10:1)得到产物15,其产率61%。
1H NMR(400MHz,CDCl3):δ8.08-8.06(m,2H),7.70-7.68(m,2H),7.10(d,J=8.4Hz,2H),6.73(d,J=8.5Hz,2H),3.95(s,2H),2.25ppm(s,3H);13C NMR(100MHz,CDCl3):δ185.5,184.8,154.1,145.6,144.1,133.5,133.49,132.0,131.97,130.0,129.8,126.4,126.3,115.5,31.5,13.2ppm;Mp:170.3-170.6℃.
实施例16
化合物16的合成
空气中,25mL反应瓶中依次加入醋酸亚铁(0.04mmol),异丝氨酸(0.35mmol),底物16a(0.5mmol),三氟乙醇(2.0mL)和水(1.0mL),2-(3,5-二甲基苯基)丙-2-醇(3mmol)和叔丁基过氧化氢(2mmol)。室温下混合均匀后,反应混合物在100℃下反应18h。加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=5:1)得到产物16,其产率78%。
实施例17
化合物17的合成
空气中,25mL反应瓶中依次加入溴化铁(0.15mmol),L-苏氨酸(0.06mmol),底物17a(0.5mmol),乙腈(2.0mL)和水(1.5mL),2-(3-甲氧基苯基)丙-2-醇(2.5mmol)和二叔丁基过氧化物(1.5mmol)。室温下混合均匀后,反应混合物在120℃下反应15h。反应结束,直接层析分离(石油醚:乙酸乙酯V/V=10:3)得到产物17,其产率72%。
实施例18
化合物18的合成
空气中,25mL反应瓶中依次加入草酸亚铁(0.1mmol),N-BOC-N'-三苯甲基-L-组氨酸(0.1mmol),底物18a(0.5mmol),甘油(1.5mL)和水(0.5mL),2-苯基-2-丙醇(1mmol)和过氧化苯甲酰(1mmol)。室温下混合均匀后,反应混合物在80℃下反应6h。反应结束,直接层析分离(石油醚:二氯甲烷V/V=20:1)得到产物18,其产率59%。
1H NMR(400MHz,CDCl3):δ7.83(s,1H),7.79(s,1H),6.76(s,1H),2.38(s,6H),2.16ppm(s,3H);13C NMR(100MHz,CDCl3):δ185.8,185.4,147.9,143.4,143.3,135.5,130.2,130.1,127.5,127.1,20.2,16.4ppm;Mp:71.5-72.6℃.
实施例19
化合物19的合成
空气中,25mL反应瓶中依次加入硫酸亚铁铵(0.06mmol),BOC-D-苯丙氨酸(0.1mmol),底物19a(0.5mmol),异丙醇(1.5mL)和水(2.5mL),2-(3-甲氧基苯基)丙-2-醇(1.5mmol)和间氯过氧苯甲酸(1.5mmol)。室温下混合均匀后,反应混合物在75℃下反应12h。反应结束,直接层析分离(石油醚:二氯甲烷V/V=10:1)得到产物19,其产率48%。
1H NMR(400MHz,CDCl3):δ8.63(s,1H),8.59(s,1H),8.07-8.03(m,2H),7.70-7.67(m,2H),6.95(s,1H),2.25ppm(s,3H);13C NMR(100MHz,CDCl3):δ185.2,184.6,149.7,137.2,134.8,134.76,130.2,130.1,129.4,129.36,128.9,128.86,128.61,128.4,16.8ppm;Mp:183.1-184.5℃.
实施例20
化合物20的合成
空气中,25mL反应瓶中依次加入酞菁亚铁(0.08mmol),L-酪氨酸(0.16mmol),底物20a(0.5mmol),甲醇(0.5mL)和水(1.5mL),2-(3,5-二甲基苯基)丙-2-醇(1.25mmol)和过氧乙酸(1.5mmol)。室温下混合均匀后,反应混合物在120℃下反应2h。反应结束,加入水5mL,并用乙醚萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=10:1)得到产物20,其产率77%。
实施例21
化合物21的合成
空气中,25mL反应瓶中依次加入三氯化铁(0.05mmol),L-色氨酸(0.25mmol),底物21a(0.5mmol),乙醇(1.0mL)和水(2.0mL),2-苯基-2-丙醇(0.75mmol)和过氧化氢(2mmol)。室温下混合均匀后,反应混合物在80℃下反应18h。反应结束,直接层析分离(石油醚:乙酸乙酯V/V=10:1)得到产物21,其产率73%。
实施例22
化合物22的合成
空气中,25mL反应瓶中依次加入高氯酸铁(III)水合物(0.04mmol),BOC-甘氨酸-甘氨酸-甘氨酸(0.15mmol),底物22a(0.5mmol),环戊醇(2.0mL)和水(2.0mL),2-(2-氯苯基)丙-2-醇(1.1mmol)和过硫酸钾(1.5mmol)。室温下混合均匀后,反应混合物在110℃下反应1.5h。反应结束,直接层析分离(石油醚:乙酸乙酯V/V=10:1)得到产物22,其产率75%。
1H NMR(400MHz,CDCl3):δ5.81(s,1H),3.77(s,3H),2.18(s,3H),1.38ppm(s,9H);13C NMR(100MHz,CDCl3):δ187.5,184.3,159.5,151.7,141.1,105.5,56.2,37.0,31.0,14.6ppm.
实施例23
化合物23的合成
空气中,25mL反应瓶中依次加入苯甲酰丙酮铁(0.1mmol),L-高胱氨酸(0.25mmol),底物23a(0.5mmol),异戊醇(2.0mL)和水(2.0mL),2-(4-溴苯基)丙-2-醇(0.8mmol)和过硫酸钠(2.5mmol)。室温下混合均匀后,反应混合物在85℃下反应4h。反应结束,直接层析分离(石油醚:乙酸乙酯V/V=20:1)得到产物23,其产率80%。
1H NMR(400MHz,CDCl3):δ7.23(d,J=8.0Hz,2H),7.03(d,J=8.0Hz,2H),2.39(s,3H),2.08(s,3H),2.05(s,3H),1.95ppm(s,3H);13C NMR(100MHz,CDCl3):δ188.1,186.7,143.4,140.8,140.6,140.5,138.2,130.4,129.3,128.7,21.3,14.0,12.5,12.45ppm;Mp:62.0-62.5℃.
实施例24
化合物24的合成
空气中,25mL反应瓶中依次加入醋酸亚铁(0.12mmol),D-缬氨酸(0.12mmol),底物24a(0.5mmol),二甲基亚砜(1.0mL)和水(3.0mL),2-苯基-2-丙醇(1mmol)和单过硫酸氢钾(2mmol)。室温下混合均匀后,反应混合物在60℃下反应9h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,用水洗涤(5mL×3),收集有机相,减压蒸除溶剂后柱层析分离(石油醚:二氯甲烷V/V=10:1)得到产物24,其产率61%。
1H NMR(400MHz,CDCl3):δ6.54(s,1H),2.52(s,3H),2.14(s,3H),1.27ppm(s,9H);13C NMR(100MHz,CDCl3):δ185.2,183.3,157.1,147.2,141.9,131.4,35.7,29.2,17.5,13.8ppm;HRMS(ESI)calcd.for C12H17O2S+[M+H+]m/z225.09438,found 225.0947.
实施例25
化合物25的合成
空气中,25mL反应瓶中依次加入三氟甲磺酸铁(0.08mmol),BOC-L-谷氨酸(0.1mmol),底物25a(0.5mmol),甲苯(1.0mL)和水(3.0mL),2-(3-甲氧基苯基)丙-2-醇(1mmol)和过氧化二异丙苯(2mmol)。室温下混合均匀后,反应混合物在100℃下反应18h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=4:1)得到产物25,其产率80%。
1H NMR(400MHz,CDCl3):δ9.53(s,1H),7.31-7.28(m,4H),7.22-7.18(m,1H),4.35(t,J=7.7Hz,1H),2.66-2.59(m,1H),2.49-2.44(m,1H),2.43-2.37(m,2H),2.10(s,3H),2,00(s,3H),1.98ppm(s,3H);13C NMR(100MHz,CDCl3):δ187.6,186.9,179.3,144.6,142.1,141.1,140.9,140.3,128.4,127.8,126.4,42.7,32.4,26.5,12.5,12.4ppm.
实施例26
化合物26的合成
空气中,25mL反应瓶中依次加入三氟甲磺酸铁(0.08mmol),BOC-L-脯氨酸(0.1mmol),底物26a(0.5mmol),乙腈(2.0mL)和水(2.0mL),2-苯基-2-丙醇(1.5mmol)和过硫酸钾(1.5mmol)。室温下混合均匀后,反应混合物在100℃下反应12h。反应结束,加入水5mL,并用乙酸乙酯萃取(5mL×3),合并有机相,减压蒸除溶剂后柱层析分离(石油醚:乙酸乙酯V/V=4:1)得到产物26,其产率60%。
1H NMR(400MHz,CDCl3):δ2.76-2.72(m,2H),2.08(s,3H),2.06(s,3H),1.59-1.55(m,3H),1.52-1.47(m,3H),1.41-1.24(m,9H),1.16-1.11(m,4H),1.09-1.03(m,4H),0.86-0.82ppm(m,15H);13C NMR(100MHz,CDCl3):δ184.1,179.6,149.3,141.0,140.7,135.1,72.6,42.1,39.3,37.5,37.4,37.4,37.2,32.8,32.7,27.9,26.5,26.0,24.8,24.5,22.7,22.6,21.3,19.7,19.7,13.2,12.6ppm;HRMS(ESI)calcd.for C28H47BrO3Na+[M+Na+]m/z533.2601,found 533.2606.
实施例1~26的原料和产物结构式及对应的实验结果如下表1所示:
表1
实施例27
实施例27与实施例23的方法相同,不同之处在于:溶剂N,N-二乙酰胺和水,有机溶剂与水的体积比为2:1。
实施例28
实施例28与实施例23的方法相同,不同之处在于:反应的温度为65℃、时间为15小时。
实施例29
实施例29与实施例23的方法相同,不同之处在于:溶剂全部为水,总体积保持不变。
对比例1
对比例1与实施例23的方法相同,不同之处在于:不加入铁催化剂,目标产物产率为0。
对比例2
对比例2与实施例23的方法相同,不同之处在于:不加入氨基酸类配体,反应产率大大降低,产率小于20%。
对比例3
对比例3与实施例23的方法相同,不同之处在于:不加入氧化剂,目标产物产率为0。
对比例4
对比例4与实施例23的方法相同,不同之处在于:采用非氨基酸类配体1,10-菲罗啉,产率仅为6%。
对比例5
对比例5与实施例23的方法相同,不同之处在于:使用卟啉铁作为催化剂,目标产物产率为0。
对比例6
对比例6与实施例23的方法相同,不同之处在于:使用高锰酸钾作为氧化剂,目标产物产率仅为16%。
对比例7与实施例23的方法相同,不同之处在于:使用的甲基化试剂为叔丁醇,目标产物产率仅为5%。
以上所述,仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制,虽然本发明已以较佳实施例揭露如上,然而并非用以限定本发明,本发明中的各种铁催化剂理论上都能与氨基酸类配体配位形成高活性的铁催化剂物种,从而有利于反应的顺利进行和选择性的提高;氨基酸类配体是发生甲基化反应的促进剂,利用的是其可与铁配位的效果,理论上给出的各种氨基酸及其衍生物都具有配位功能,都应能取得类似之效果;各种过氧化物是氧化剂;醌类底物上发生的是碳-氢键的活化,而醌类化合物结构上的各种取代基影响的是环内的电子云密度大小以及反应时的空间位阻大小,即取代基的修饰只是一定程度上影响反应,不对反应的发生起决定作用。任何熟悉本专业的技术人员不难理解,在不脱离本发明技术方案范围内,当可进行变动或修饰得到相应的实施例,例如对于所述的取代基可在本发明范围内进行替换、改变或修饰,均可以实现本发明方法。但凡是未脱离本发明技术方案的宗旨,依据本发明的对以上实施例所作的任何修改、修饰或等同与等效的变化,均仍属于本发明技术方案的范围内。
Claims (10)
1.一种铁催化醌类化合物甲基化的方法,其特征在于,包括如下步骤:以单取代或双取代的2-芳基-2-丙醇为甲基化试剂、过氧化物为氧化剂,铁为催化剂、氨基酸或其衍生物为配体,在溶剂中氧化醌类化合物的C(sp2)-H键发生甲基化反应生成甲基取代的醌类化合物;
反应通式表示如下:
式中:所述R1表示醌类化合物中芳环上的取代基,R1单取代或双取代苯环上的氢;R2表示醌类化合物双键上的取代基,R2单取代双键上的氢;R3表示2-芳基-2-丙醇中芳基上的取代基,R3单取代或多取代芳环上的氢。
2.根据权利要求1所述的铁催化醌类化合物甲基化的方法,其特征在于,所述R1为硝基、甲氧基或甲基。
3.根据权利要求1所述的铁催化醌类化合物甲基化的方法,其特征在于,所述R2为氢、甲基、甲氧基、乙氧基、异丙氧基苯氧基、卤素、乙酰氧基或甲硫基。
4.根据权利要求1所述的铁催化醌类化合物甲基化的方法,其特征在于,R3为氢、3-甲氧基、2-氯、4-溴、3,5-二甲基或4-羧基。
5.根据权利要求1所述的铁催化醌类化合物甲基化的方法,其特征在于,所述单取代或双取代的2-芳基-2-丙醇优选选自2-苯基-2-丙醇、2-(3-甲氧基苯基)丙-2-醇、2-(2-氯苯基)丙-2-醇、2-(4-溴苯基)丙-2-醇、2-(3,5-二甲基苯基)丙-2-醇或4-(2-羟基-2-丙基)苯甲酸。
6.其中,所述铁选自三氟甲磺酸亚铁、三氟甲磺酸铁、氯化亚铁、乙酰丙酮亚铁、乙酰丙酮铁、铁氰化铁、醋酸亚铁、苯甲酰丙酮铁、硫酸亚铁、硫酸亚铁铵、硫酸铁、草酸亚铁、草酸铁、氟化亚铁、氟化铁、溴化亚铁、溴化铁、碘化亚铁、氯化亚铁、三氯化铁、高氯酸铁水合物、1,1'-双(二苯基膦)二茂铁、酞菁亚铁、硝酸铁、氧化铁或四氧化三铁中的任意一种或者多种。
7.根据权利要求1所述的铁催化醌类化合物甲基化的方法,其特征在于,所述配体选自S-乙酰氨基甲基-N-叔丁氧羰基-L-半胱氨酸、N-乙酰-L-半胱氨酸、N,N'-双(叔丁氧羰基)-L-胱氨酸、L-丝氨酸、D-胱氨酸、天冬氨酸、D-精氨酸、异丝氨酸、L-苏氨酸、L-酪氨酸、BOC-L-脯氨酸、BOC-甘氨酸-甘氨酸-甘氨酸、2-烯丙基-N-FMOC-L-甘氨酸、BOC-D-苯丙氨酸、L-半胱氨酸、D-丝氨酸、β-硫基缬氨酸、D-脯氨酸、D-缬氨酸、L-脯氨酸、L-苯丙氨酸、N-BOC-N'-三苯甲基-L-组氨酸、L-色氨酸、N-BOC-L-亮氨酸、L-组氨酸、BOC-L-谷氨酸、L-胱氨酸或者L-高胱氨酸中的任意一种或者多种。
8.根据权利要求1所述的铁催化醌类化合物甲基化的方法,其特征在于,所述氧化剂选自过硫酸钾、过硫酸铵、过硫酸钠、叔丁基过氧化氢、过氧化氢、过氧乙酸、间氯过氧苯甲酸、过氧化苯甲酰、二叔丁基过氧化物、单过硫酸氢钾、过氧化二异丙苯、2-过氧化丁酮或者双(三甲基硅基)过氧化物中的任意一种或者多种。
9.根据权利要求1所述的铁催化醌类化合物甲基化的方法,其特征在于,所述溶剂为有机溶剂、水或有机溶剂的水溶液,所述有机溶剂选自甲醇、乙醇、乙二醇、正丙醇、异丙醇、1,3-丙二醇、甘油、正丁醇、异丁醇、叔丁醇、三氟乙醇、2-甲基-2-丁醇、3-甲氧基丁醇、仲丁醇、叔戊醇、4-甲基-2-戊醇、异戊醇、2-戊醇、3-戊醇、环戊醇、正戊醇、聚乙二醇200-10000、乙腈、苯腈、甲苯、丙酮、二氯甲烷、1,2-二氯乙烷、二甲亚砜、N,N-二甲酰胺、N,N-二乙酰胺、乙酸乙酯、1,4-二氧六环或四氢呋喃,所述溶剂为有机溶剂的水溶液时,所述有机溶剂与水的体积比为1:(0.1~10)。
10.根据权利要求1所述的铁催化醌类化合物甲基化的方法,其特征在于,所述醌类化合物、单取代或双取代的2-芳基-2-丙醇、过氧化物、氨基酸或其衍生物、铁催化剂的摩尔比为1:(1.2~50):(2~50):(0.002~20):(0.001~10);反应的温度为40~120℃、时间为0.5~48小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410203401.0A CN118047669A (zh) | 2024-02-23 | 2024-02-23 | 一种铁催化醌类化合物甲基化的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410203401.0A CN118047669A (zh) | 2024-02-23 | 2024-02-23 | 一种铁催化醌类化合物甲基化的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118047669A true CN118047669A (zh) | 2024-05-17 |
Family
ID=91049801
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410203401.0A Pending CN118047669A (zh) | 2024-02-23 | 2024-02-23 | 一种铁催化醌类化合物甲基化的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118047669A (zh) |
-
2024
- 2024-02-23 CN CN202410203401.0A patent/CN118047669A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Denney et al. | A convenient method for the preparation of some optically active allylic alcohols1 | |
Zhao et al. | Copper on charcoal: Cu 0 nanoparticle catalysed aerobic oxidation of α-diazo esters | |
Hon et al. | Acetonyltriphenylphosphonium bromide in organic synthesis: a useful catalyst in the cyclotrimerization of aldehydes | |
CN118047669A (zh) | 一种铁催化醌类化合物甲基化的方法 | |
CN107032939B (zh) | α,β-不饱和硝基烯烃衍生物的合成方法 | |
CN114085150B (zh) | 一种beta-(-)-L-薄荷基-丙烯酸酯类化合物的合成方法及其在卷烟中的应用 | |
Ye et al. | Cu2O‐Mediated Room Temperature Cyanation of Aryl Boronic Acids/Esters and TMSCN | |
JPH07247289A (ja) | クロメンオキシド類の製造方法 | |
CN112961054B (zh) | 一种铁催化芳香族化合物乙氧羰基二氟甲基化的方法 | |
US5446166A (en) | Preparation of pyrrol and oxazole compounds: formation of porphyrins and C-acyl-α-amino acid esters therefrom | |
CN113004146A (zh) | 一种烯醇醚催化氧化制备烯醛的方法 | |
Loghmani-Khouzani et al. | A convenient synthesis of azines under solvent-free conditions using microwave irradiation | |
Li et al. | Enantioselective Allylic Oxidation of Olefins Using Chiral Quinolinyl‐oxazoline Copper Complex Catalysts | |
Lal et al. | Allylsilane as a versatile handle in photoredox catalysis | |
CN106995372A (zh) | 一种基于四芳基卟啉铁催化合成(E)‑β‑硝基苯乙烯衍生物的方法 | |
CN106995373A (zh) | 以碘化铵为硝基源一锅合成α,β‑不饱和硝基烯烃衍生物的方法 | |
CN118047668A (zh) | 一种铁催化苄位c-h键与醌类化合物脱氢偶联的方法 | |
CN107417535A (zh) | 一种高选择性(E)‑β‑硝基苯乙烯衍生物的一锅合成方法 | |
CN114957174B (zh) | 一种烷基取代的α-亚甲基-γ-丁内酯衍生物及其合成方法 | |
Mohammadpoor-Baltork et al. | Convenient transformation of thiocarbonyl to carbonyl group using benzyltriphenylphosphonium and n-butyltriphenylphosphonium peroxodisulfates | |
CN110981702B (zh) | 一种2,3-二溴苯酚或其衍生物的高效合成方法 | |
CN110407677B (zh) | 二苯乙二酮类化合物的制备方法及应用 | |
US4401828A (en) | Process for preparing phenoxybenzoic acids | |
CN116199572A (zh) | 一种铁催化酮α位溴化的方法 | |
Lo | Part 1: Synthesis of 3, 7 dimethyl-7-methoxyoctane-2-ol (Osyrol) from Citronellol utilizing the Wacker Process Part 2: Developing a methodology for C (sp3)-H Arylation on the β Position of a Carboxylic Acid using a Removable Directing Group |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |